Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com

Please find enclosed a Press Release on

"Dr. Reddy's Laboratories announces entering into a definitive agreement to sell its neurology branded products

to Upsher-Smith Laboratories, LLC"

This is for your information.

CC:- New York Stock Exchange Inc.(Stock Code: RDY)

Laboratories announces entering into a definitive agreement to sell its neurology branded products to Upsher-Smith Laboratories,

Hyderabad, India and Princeton,

NJ, USA. June 14, 2019 - Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announces that it has entered

into a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC (Upsher-Smith), pursuant to which Dr. Reddy's

would sell its US and select territory rights for ZEMBRACE SYMTOUCH

(sumatriptan injection) 3 mg and TOSYMRATM (sumatriptan nasal spray) 10 mg, (formerly

referred to as "DFN-02"), which are commercialized through its wholly owned subsidiary, Promius Pharma, LLC.

Under the agreement, Dr.Reddy's will receive U.S.$70 million

as upfront consideration, U.S.$40.5 million in near term milestones and additional financial considerations including, existing

contractual obligation and inventory. Subsequently, Dr. Reddy's will receive sales based royalties on a quarterly basis.

The closing of the transaction is subject to various customary

closing conditions including antitrust review under Hart-Scott-Rodino Act.

"This is a testament to our strong R&D capabilities,

and delivering solutions to unmet needs of patients. In a short time, we created a well-recognized migraine specialty business

in the US and we look forward to our partnership with Upsher-Smith" said G.V. Prasad, Co-Chairman and CEO, Dr. Reddy's

Laboratories Limited.

"Tosymra and Zembrace were designed and developed with

the goal of addressing unmet needs of large but discrete segments of patients suffering from episodic migraine who need options

other than their current therapies. We are excited to partner with Upsher-Smith which has established a strong presence in neurology"

said Anil Namboodiripad, Ph.D., Senior Vice President, Proprietary Products and Head, Promius Pharma.

Important Patient Safety Information for Zembrace SymTouch

(sumatriptan injection) 3 mg and TOSYMRA (sumatriptan nasal spray) 10 mg.

Zembrace SymTouch and TOSYMRA can cause serious side effects,

including: heart attack and other heart problems, which may lead to death.

Do not use Zembrace SymTouch and TOSYMRA if you have:

You are encouraged to report negative side effects of prescription

drugs. To report SUSPECTED SIDE EFFECTS, call Promius Pharma at 1-888-966-8766 or contact the FDA at 1-800-FDA-1088 (1-800-332-1088)

or online at http://www.fda.gov/Safety/MedWatch

Please see Full Prescribing Information for Zembrace SymTouch

For more information, please visit www.zembrace.com and

About Dr. Reddy's: Dr. Reddy's Laboratories

Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative

medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics

and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical

services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular,

diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets

include - USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

About Promius Pharma LLC: Promius Pharma is a wholly-owned

subsidiary of Dr. Reddy's Laboratories, one of the largest and most respected pharmaceutical companies in the world. Promius

Pharma is committed to bringing new products to market that meet patients' needs. For more information, log on to: www.promiuspharma.com.

About Upsher Smith LLC:

Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients

through an unwavering commitment to high-quality products and sustainable growth. Since 1919, it has brought generics and brands

to a wide array of customers backed by an attentive level of service, strong industry relationships, and dedication to uninterrupted

supply. For more information, visit www.upsher-smith.com.

Disclaimer: This press release may include statements

of future expectations and other forward-looking statements that are based on the management's current views and assumptions

and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially

from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the

words "may", "will", "should", "expects", "plans", "intends", "anticipates",

"believes", "estimates", "predicts", "potential", or "continue" and similar expressions

identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements

due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency

exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity

levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and

in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration

The company assumes no obligation to update any information